Influenzavirus B Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Influenza Virus B Infections pipeline market research report provides comprehensive information on the therapeutics under development for Influenza Virus B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza Virus B Infections and features dormant and discontinued projects.
Key Targets in the Influenza Virus B Infections Pipeline Market
The key targets in the Influenza Virus B Infections pipeline market are Hemagglutinin, Hemagglutinin HA, Exo Alpha Sialidase, Polymerase Acidic Protein, 2019 Novel corona Virus Spike Glycoprotein, Envelope Protein M, Glucocorticoid Receptor, and Hemagglutinin 1. Hemagglutinin has the highest number of pipeline products in the Influenza Virus B Infections pipeline market.
Influenza Virus B Infections pipeline market, by Targets
For more target insights, download a free report sample
Key Types of Moa in the Influenza Virus B Infections Pipeline Market
The key types of MoA in the Influenza Virus B Infections pipeline market are Hemagglutinin Inhibitor, Exo Alpha Sialidase Inhibitor, Polymerase Acidic Protein Inhibitor, Envelope Protein M Inhibitor, Glucocorticoid Receptor Agonist, Hemagglutinin HA Inhibitor, Influenza M2 Proton Channel Blocker, and Nuclear Factor Kappa B Inhibitor. Hemagglutinin Inhibitor has the highest number of pipeline products.
Influenza Virus B Infections pipeline market, by Types of MoA
For more MoA insights, download a free report sample
Key Types of Roa in the Influenza Virus B Infections Pipeline Market
The key types of RoA in the Influenza Virus B Infections pipeline market are intramuscular, oral, nasal, inhalational, parenteral, subcutaneous, transdermal, and intravenous. Intramuscular has the maximum number of pipeline products.
Influenza Virus B Infections pipeline market, by Types of RoA
For more ROA insights, download a free report sample
Key Molecule Types in the Influenza Virus B Infections Pipeline Market
The key molecule types in the Influenza Virus B Infections pipeline market are small molecule, inactivated vaccine, subunit vaccine, monoclonal antibody, mRNA vaccine, live attenuated vaccine, monoclonal antibody conjugated, and vaccine. Small molecule has the highest number of pipeline products.
Influenza Virus B Infections pipeline market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Influenza Virus B Infections Pipeline Market
The key companies in the Influenza Virus B Infections pipeline market are Moderna Inc, Adimmune Corp, Cidara Therapeutics Inc, Shionogi & Co Ltd, Aphios Corp, CSL Ltd, Sanofi, and TaiGen Biotechnology Co Ltd. Moderna Inc has the highest number of pipeline products.
Influenza Virus B Infections pipeline market, by Companies
To know more about companies, download a free report sample
Market report overview
Key Targets | Hemagglutinin, Hemagglutinin HA, Exo Alpha Sialidase, Polymerase Acidic Protein, 2019 Novel corona Virus Spike Glycoprotein, Envelope Protein M, Glucocorticoid Receptor, and Hemagglutinin 1 |
Key MoA Types | Hemagglutinin Inhibitor, Exo Alpha Sialidase Inhibitor, Polymerase Acidic Protein Inhibitor, Envelope Protein M Inhibitor, Glucocorticoid Receptor Agonist, Hemagglutinin HA Inhibitor, Influenza M2 Proton Channel Blocker, and Nuclear Factor Kappa B Inhibitor |
Key RoA Types | Intramuscular, Oral, Nasal, Inhalational, Parenteral, Subcutaneous, Transdermal, and Intravenous |
Key Molecule Types | Small Molecule, Inactivated Vaccine, Subunit Vaccine, Monoclonal Antibody, mRNA Vaccine, Live Attenuated Vaccine, Monoclonal Antibody Conjugated, and Vaccine |
Key Companies | Moderna Inc, Adimmune Corp, Cidara Therapeutics Inc, Shionogi & Co Ltd, Aphios Corp, CSL Ltd, Sanofi, and TaiGen Biotechnology Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza Virus B Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenza Virus B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza Virus B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenza Virus B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza Virus B Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza Virus B Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza Virus B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Abhelix LLC
Adimmune Corp
Allergy Therapeutics Plc
Andikang (Wuxi) Biotechnology Co Ltd
Ansun Biopharma Inc
Aphios Corp
AstraZeneca Plc
AusBio Ltd
AVM Biotechnology LLC
BioNTech SE
Biotron Ltd
BlueWillow Biologics Inc
Changchun Bcht Biotechnology Co Ltd
Cidara Therapeutics Inc
Cocrystal Pharma Inc
ContraFect Corp
CSL Ltd
DAE HWA Pharmaceutical Co Ltd
e-Therapeutics Plc
Evotec SE
Evrys Bio
FUJIFILM Toyama Chemical Co Ltd
Ginkgo Tree Pharmaceutical (Suzhou) Co Ltd
Hangzhou Zenshine Pharmaceuticals Co Ltd
Imutex Ltd
Inovio Pharmaceuticals Inc
iQur Ltd
Jiangsu Ab&b Biotechnology Co Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Kangrun Biological Technology Co Ltd
Johnson & Johnson
Kentucky BioProcessing Inc
Liaoning Cheng Da Biotechnology Co Ltd
Moderna Inc
Novavax Inc
Novo Medi Sciences Pvt Ltd
Orlance Inc
Park of Active Molecules
Pentavalent Bio Sciences Pvt Ltd
Revelation Biosciences Inc
Romark Laboratories LC
SAB Biotherapeutics Inc
Sanofi
Seqirus Ltd
Serum Institute of India Pvt Ltd
Shanghai Institute of Biological Products Co Ltd
Shionogi & Co Ltd
Symvivo Inc
TaiGen Biotechnology Co Ltd
Therapeutic Systems Research Laboratories Inc
Trellis Bioscience Inc
UMN Pharma Inc
Vacthera BioTech GmbH
Ventaleon GmbH
Vir Biotechnology Inc
Viramatix Sdn Bhd
Walvax Biotechnology Co Ltd
Wuhan Institute of Biological Products Co Ltd
Zosano Pharma Corp
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Influenza Virus B Infections pipeline market?
The key targets in the Influenza Virus B Infections pipeline market are Hemagglutinin, Hemagglutinin HA, Exo Alpha Sialidase, Polymerase Acidic Protein, 2019 Novel corona Virus Spike Glycoprotein, Envelope Protein M, Glucocorticoid Receptor, and Hemagglutinin 1.
-
What are the key types of MoA in the Influenza Virus B Infections pipeline market?
The key types of MoA in the Influenza Virus B Infections pipeline market are Hemagglutinin Inhibitor, Exo Alpha Sialidase Inhibitor, Polymerase Acidic Protein Inhibitor, Envelope Protein M Inhibitor, Glucocorticoid Receptor Agonist, Hemagglutinin HA Inhibitor, Influenza M2 Proton Channel Blocker, and Nuclear Factor Kappa B Inhibitor.
-
What are the key types of RoA in the Influenza Virus B Infections pipeline market?
The key types of RoA in the Influenza Virus B Infections pipeline market are Intramuscular, Oral, Nasal, Inhalational, Parenteral, Subcutaneous, Transdermal, and Intravenous.
-
What are the key molecule types in the Influenza Virus B Infections pipeline market?
The key molecule types in the Influenza Virus B Infections pipeline market are Small Molecule, Inactivated Vaccine, Subunit Vaccine, Monoclonal Antibody, mRNA Vaccine, Live Attenuated Vaccine, Monoclonal Antibody Conjugated, and Vaccine.
-
What are the key companies in the Influenza Virus B Infections pipeline market?
The key companies in the Influenza Virus B Infections pipeline market are Moderna Inc, Adimmune Corp, Cidara Therapeutics Inc, Shionogi & Co Ltd, Aphios Corp, CSL Ltd, Sanofi, and TaiGen Biotechnology Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.